Vaxcyte Doses First Participant in VAX-A1 Phase 1 Vaccine Trial
Vaxcyte begins Phase 1 study for Group A Streptococcus vaccine, targeting topline data in late 2027. Vaxcyte Inc. (NASDAQ:PCVX) has initiated dosing in its Phase 1 trial for VAX-A1, an investigational vaccine targeting Group A Streptococcus. The first participant received